Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1

Rae Lynn Baldwin, Murray Korc

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Pancreatic cancer is an extremely aggressive malignancy. The factors allowing human pancreatic cancer cells to escape normal growth constraints are not known. However, it has been proposed that certain cancer cells may obtain a growth advantage as the result of a lack of responsiveness to negative growth regulators such as transforming growth factor-beta 1 (TGF-β1). We now show that two established pancreatic carcinoma cell lines, COLO 357 and PANC-I, are sensitive to growth inhibition by TGF-β1. The growth of COLO 357 cells is inhibited by 50% when incubated in the presence of TGF-β1 (5 ng/ml) under low serum conditions (0.5%). PANC-I cells are growth inhibited by 25% under the same conditions. In COLO 357 cells, but not PANC-I cells, TGF-β1 also causes a marked alteration in cell morphology. In both cell lines, TGF-β1 induces TGF-β1 mRNA levels in a time and dose-dependent manner. However, TGFβ1 does not increase the amount of TGF-β2 or TGF-β3 mRNA in these cells. In spite of its growth inhibitory effects, TGF-β1 fails to suppress c-myc mRNA levels. These findings suggest that TGF-β1 inhibits the growth of human pancreatic cancer cells and point to a significant dysfunction in the ability of TGF-β1 to suppress c-myc expression in these cells.

Original languageEnglish (US)
Pages (from-to)23-34
Number of pages12
JournalGrowth Factors
Volume8
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Transforming Growth Factor beta
Cells
Growth
Pancreatic Neoplasms
Cell growth
Messenger RNA
Pancreatic Carcinoma
Transforming Growth Factor beta1
Cell Line
Human engineering
Neoplasms
Serum

Keywords

  • 3-4
  • 5-dimethylthiazol-2-yl-2
  • 5-diphenyltetrazolium bromide
  • Autoinduction
  • C-myc
  • EGF
  • Epidermal growth factor; FBS
  • Fetal bovine serum; MTT
  • Growth inhibition
  • Pancreatic cancer
  • TGF-β1
  • Transforming growth factor beta 1; EGF

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. / Baldwin, Rae Lynn; Korc, Murray.

In: Growth Factors, Vol. 8, No. 1, 1993, p. 23-34.

Research output: Contribution to journalArticle

Baldwin, Rae Lynn ; Korc, Murray. / Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. In: Growth Factors. 1993 ; Vol. 8, No. 1. pp. 23-34.
@article{834fbbfab2f04816b8c3f2c8c56bcf8d,
title = "Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1",
abstract = "Pancreatic cancer is an extremely aggressive malignancy. The factors allowing human pancreatic cancer cells to escape normal growth constraints are not known. However, it has been proposed that certain cancer cells may obtain a growth advantage as the result of a lack of responsiveness to negative growth regulators such as transforming growth factor-beta 1 (TGF-β1). We now show that two established pancreatic carcinoma cell lines, COLO 357 and PANC-I, are sensitive to growth inhibition by TGF-β1. The growth of COLO 357 cells is inhibited by 50{\%} when incubated in the presence of TGF-β1 (5 ng/ml) under low serum conditions (0.5{\%}). PANC-I cells are growth inhibited by 25{\%} under the same conditions. In COLO 357 cells, but not PANC-I cells, TGF-β1 also causes a marked alteration in cell morphology. In both cell lines, TGF-β1 induces TGF-β1 mRNA levels in a time and dose-dependent manner. However, TGFβ1 does not increase the amount of TGF-β2 or TGF-β3 mRNA in these cells. In spite of its growth inhibitory effects, TGF-β1 fails to suppress c-myc mRNA levels. These findings suggest that TGF-β1 inhibits the growth of human pancreatic cancer cells and point to a significant dysfunction in the ability of TGF-β1 to suppress c-myc expression in these cells.",
keywords = "3-4, 5-dimethylthiazol-2-yl-2, 5-diphenyltetrazolium bromide, Autoinduction, C-myc, EGF, Epidermal growth factor; FBS, Fetal bovine serum; MTT, Growth inhibition, Pancreatic cancer, TGF-β1, Transforming growth factor beta 1; EGF",
author = "Baldwin, {Rae Lynn} and Murray Korc",
year = "1993",
doi = "10.3109/08977199309029131",
language = "English (US)",
volume = "8",
pages = "23--34",
journal = "Growth Factors",
issn = "0897-7194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1

AU - Baldwin, Rae Lynn

AU - Korc, Murray

PY - 1993

Y1 - 1993

N2 - Pancreatic cancer is an extremely aggressive malignancy. The factors allowing human pancreatic cancer cells to escape normal growth constraints are not known. However, it has been proposed that certain cancer cells may obtain a growth advantage as the result of a lack of responsiveness to negative growth regulators such as transforming growth factor-beta 1 (TGF-β1). We now show that two established pancreatic carcinoma cell lines, COLO 357 and PANC-I, are sensitive to growth inhibition by TGF-β1. The growth of COLO 357 cells is inhibited by 50% when incubated in the presence of TGF-β1 (5 ng/ml) under low serum conditions (0.5%). PANC-I cells are growth inhibited by 25% under the same conditions. In COLO 357 cells, but not PANC-I cells, TGF-β1 also causes a marked alteration in cell morphology. In both cell lines, TGF-β1 induces TGF-β1 mRNA levels in a time and dose-dependent manner. However, TGFβ1 does not increase the amount of TGF-β2 or TGF-β3 mRNA in these cells. In spite of its growth inhibitory effects, TGF-β1 fails to suppress c-myc mRNA levels. These findings suggest that TGF-β1 inhibits the growth of human pancreatic cancer cells and point to a significant dysfunction in the ability of TGF-β1 to suppress c-myc expression in these cells.

AB - Pancreatic cancer is an extremely aggressive malignancy. The factors allowing human pancreatic cancer cells to escape normal growth constraints are not known. However, it has been proposed that certain cancer cells may obtain a growth advantage as the result of a lack of responsiveness to negative growth regulators such as transforming growth factor-beta 1 (TGF-β1). We now show that two established pancreatic carcinoma cell lines, COLO 357 and PANC-I, are sensitive to growth inhibition by TGF-β1. The growth of COLO 357 cells is inhibited by 50% when incubated in the presence of TGF-β1 (5 ng/ml) under low serum conditions (0.5%). PANC-I cells are growth inhibited by 25% under the same conditions. In COLO 357 cells, but not PANC-I cells, TGF-β1 also causes a marked alteration in cell morphology. In both cell lines, TGF-β1 induces TGF-β1 mRNA levels in a time and dose-dependent manner. However, TGFβ1 does not increase the amount of TGF-β2 or TGF-β3 mRNA in these cells. In spite of its growth inhibitory effects, TGF-β1 fails to suppress c-myc mRNA levels. These findings suggest that TGF-β1 inhibits the growth of human pancreatic cancer cells and point to a significant dysfunction in the ability of TGF-β1 to suppress c-myc expression in these cells.

KW - 3-4

KW - 5-dimethylthiazol-2-yl-2

KW - 5-diphenyltetrazolium bromide

KW - Autoinduction

KW - C-myc

KW - EGF

KW - Epidermal growth factor; FBS

KW - Fetal bovine serum; MTT

KW - Growth inhibition

KW - Pancreatic cancer

KW - TGF-β1

KW - Transforming growth factor beta 1; EGF

UR - http://www.scopus.com/inward/record.url?scp=0027538329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027538329&partnerID=8YFLogxK

U2 - 10.3109/08977199309029131

DO - 10.3109/08977199309029131

M3 - Article

VL - 8

SP - 23

EP - 34

JO - Growth Factors

JF - Growth Factors

SN - 0897-7194

IS - 1

ER -